These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33792222)

  • 61. Brentuximab vedotin in CD30
    Stranzenbach R; Dippel E; Schlaak M; Stadler R
    Br J Dermatol; 2017 Dec; 177(6):1503-1509. PubMed ID: 28703284
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Brentuximab vedotin as a single agent in the treatment of a pediatric primary cutaneous CD30
    Ceglie G; De Vito R; Cossutta M; Tiberi A; Carta R; Boccieri E; Palumbo G
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29626. PubMed ID: 35322542
    [No Abstract]   [Full Text] [Related]  

  • 63. Challenging diagnoses in oral ulcers with large atypical CD30+ cells: EBV-positive mucocutaneous ulcer differentials.
    Rodrigues Lacet DF; Oliveira CC
    J Clin Exp Hematop; 2020 Mar; 60(1):19-23. PubMed ID: 32037353
    [No Abstract]   [Full Text] [Related]  

  • 64. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
    Zinzani PL; Sasse S; Radford J; Shonukan O; Bonthapally V
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):359-69. PubMed ID: 25964164
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
    BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
    Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
    Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Brentuximab a novel antibody therapy: real-world use confirms efficacy and tolerability for CD30-positive cutaneous lymphoma.
    Engelina S; Saggu M; Yoo J; Shah F; Stevens A; Irwin C; Chaganti S; Scarisbrick JJ
    Br J Dermatol; 2020 Mar; 182(3):799-800. PubMed ID: 31529492
    [No Abstract]   [Full Text] [Related]  

  • 68. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
    Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
    Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
    Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
    Bossard C; Dobay MP; Parrens M; Lamant L; Missiaglia E; Haioun C; Martin A; Fabiani B; Delarue R; Tournilhac O; Delorenzi M; Gaulard P; de Leval L
    Blood; 2014 Nov; 124(19):2983-6. PubMed ID: 25224410
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
    Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
    Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.
    Forero-Torres A; Bartlett NL; Berryman RB; Chen R; Matous JV; Fanale MA; O'Connor OA; Olshefski R; Smith SE; Huebner D; Levine PL; Grove LE; Gopal AK
    Leuk Lymphoma; 2015 Apr; 56(4):1151-3. PubMed ID: 25110824
    [No Abstract]   [Full Text] [Related]  

  • 73. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma.
    Badri N; Ngamdu KS; Torabi A; Guar S
    J Cancer Res Ther; 2020; 16(1):183-185. PubMed ID: 32362635
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Brentuximab vedotin for treatment of systemic T-cell lymphoma.
    Chihara D; Oki Y
    Expert Opin Biol Ther; 2014 Oct; 14(10):1519-26. PubMed ID: 25200691
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.
    Hasanali ZS; Epner EM; Feith DJ; Loughran TP; Sample CE
    Mol Cancer Ther; 2014 Dec; 13(12):2784-92. PubMed ID: 25319394
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
    Ansell SM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity.
    Schwartz Z; Bowe RB; Coleman M; Magro CM
    Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CD30 as a therapeutic target in adult haematological malignancies: Where are we now?
    Veyri M; Spano JP; Le Bras F; Marcelin AG; Todesco E
    Br J Haematol; 2023 Jun; 201(6):1033-1046. PubMed ID: 37170397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.